Form 4: Azitra CFO Receives Stock Option Grant

Azitra, Inc. Chief Financial Officer Norm Staskey was granted 35,524 stock options as part of a compensation package.

Summary

• CFO Norm Staskey acquired 35,524 stock options on April 20, 2026.
• The options have an exercise price of $0.2127 per share.
• The options are set to expire on April 20, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $0.2127 exercise price.

Future Outlook

The options vest over a three-year period, with one-third vesting on the first anniversary and the remainder vesting monthly thereafter.

Industry Context

StockSavvy.ai notes that equity grants for C-suite executives in the biotechnology sector are standard practice for retention and performance alignment, particularly for companies in the development stage.

Comparison to Industry Standards

• The three-year vesting schedule is consistent with standard industry practices for executive compensation in small-cap biotech firms.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the first tranche of options on April 20, 2027.

Key Dates

Keywords

Azitra, AZTR, Form 4, Insider Trading, Stock Options, CFO